Prenetics Global 2025 Q3 Earnings 567.7% Revenue Surge Amid 28% Reduced Net Loss

Prenetics Global (PRE) reported a 567.7% year-over-year revenue surge to $23.55 million in Q3 2025, driven by IM8’s record performance. The company narrowed its net loss by 28% to $8.69 million, with GAAP EPS improving to -$0.53 from -$0.84. CEO Danny Yeung highlighted IM8’s $9 million October revenue and a $44 million equity raise, signaling aggressive growth plans.

Revenue

Prenetics’ total revenue surged to $23.55 million in Q3 2025, a 567.7% increase from $3.53 million in Q3 2024. IM8, the company’s premium health brand, led with $17.2 million in revenue, reflecting a 76% quarter-over-quarter jump. Europa contributed $4.0 million, while CircleDNA added $2.4 million. The performance underscores IM8’s dominance in the revenue mix, driven by global demand and strategic product expansion.

Earnings/Net Income

Prenetics narrowed its net loss to $8.69 million in Q3 2025, a 28% reduction from $12.07 million in Q3 2024. GAAP EPS improved to -$0.53 from -$0.84, though the company has sustained losses for four consecutive years. The adjusted EBITDA loss of $2.1 million marked a 54% sequential improvement, reflecting tighter cost controls and operational efficiency. Despite progress, the EPS remains a negative indicator, highlighting ongoing financial challenges.

Price Action

The stock price of Prenetics Global rose 3.44% during the latest trading day and 0.98% for the week, but fell 6.91% month-to-date. The post-earnings rally suggests investor optimism about IM8’s growth trajectory, though the monthly decline indicates broader market skepticism about long-term profitability.

Post-Earnings Price Action Review

Following the earnings release, Prenetics’ shares saw a modest intraday gain, buoyed by the revenue surge and improved net loss. However, the month-to-date decline of 6.91% suggests lingering concerns about the company’s ability to achieve sustained profitability. Analysts noted that while IM8’s performance is robust, the broader business units and Bitcoin treasury strategy remain speculative. The stock’s volatility reflects a tug-of-war between bullish revenue trends and bearish profitability metrics.

CEO Commentary

CEO Danny Yeung emphasized IM8’s “phenomenal” growth, with monthly revenue climbing from $581,000 at launch to $10 million in December 2025. He highlighted a 36% month-over-month growth rate, 60% gross margin, and a 3.9-month payback period, underscoring unit economics. The CEO also noted the company’s $120 million liquidity position and zero debt, enabling “aggressive scaling” without dilution. He expressed confidence in reaching $300 million in annual recurring revenue by 2026, positioning Prenetics as a “generational investment opportunity.”

Guidance

Prenetics reaffirmed full-year 2025 revenue guidance of $90–$100 million, with IM8 projected to contribute $60 million. For Q4 2025, the company expects IM8 revenue of $28 million, a 63% quarter-over-quarter increase. By FY 2026, IM8 aims for $180–$200 million in revenue, translating to $300 million in annual recurring revenue by year-end. The guidance reflects confidence in international expansion and product innovation.

Additional News

1. Equity Raise and Bitcoin Acquisition: Prenetics completed a $44 million equity offering in October 2025, attracting investors like Kraken and Exodus. The company also acquired 100 Bitcoin, expanding its treasury to 387 BTC ($40 million), signaling a dual-engine strategy combining health and digital assets.

2. ACT Genomics Divestiture: The $72 million sale of ACT Genomics in October 2025 streamlined operations, focusing resources on IM8 and strategic growth.

3. Institutional Investment Shifts: Hedge funds like Aberdeen Group and Morgan Stanley increased stakes in Prenetics, while UBS and Quinn Opportunity Partners reduced holdings, reflecting mixed institutional sentiment.

Image Placeholder for IM8 Product Line

Image Placeholder for Bitcoin Treasury Strategy